The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.
Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, El-Cheikh J, Granata A, Harbi S, Morabito L, Faucher C, Rimondo A, Girardi D, Mohty B, Calmels B, Carlo-Stella C, Chabannon C, Bouabdallah R, Santoro A, Vey N, Weiller PJ, Blaise D.
Crocchiolo R, et al. Among authors: vey n.
Bone Marrow Transplant. 2016 Aug;51(8):1134-6. doi: 10.1038/bmt.2016.69. Epub 2016 Mar 21.
Bone Marrow Transplant. 2016.
PMID: 26999460
No abstract available.